HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Allelic Mutations of KITLG, Encoding KIT Ligand, Cause Asymmetric and Unilateral Hearing Loss and Waardenburg Syndrome Type 2.

Abstract
Linkage analysis combined with whole-exome sequencing in a large family with congenital and stable non-syndromic unilateral and asymmetric hearing loss (NS-UHL/AHL) revealed a heterozygous truncating mutation, c.286_303delinsT (p.Ser96Ter), in KITLG. This mutation co-segregated with NS-UHL/AHL as a dominant trait with reduced penetrance. By screening a panel of probands with NS-UHL/AHL, we found an additional mutation, c.200_202del (p.His67_Cys68delinsArg). In vitro studies revealed that the p.His67_Cys68delinsArg transmembrane isoform of KITLG is not detectable at the cell membrane, supporting pathogenicity. KITLG encodes a ligand for the KIT receptor. Also, KITLG-KIT signaling and MITF are suggested to mutually interact in melanocyte development. Because mutations in MITF are causative of Waardenburg syndrome type 2 (WS2), we screened KITLG in suspected WS2-affected probands. A heterozygous missense mutation, c.310C>G (p.Leu104Val), that segregated with WS2 was identified in a small family. In vitro studies revealed that the p.Leu104Val transmembrane isoform of KITLG is located at the cell membrane, as is wild-type KITLG. However, in culture media of transfected cells, the p.Leu104Val soluble isoform of KITLG was reduced, and no soluble p.His67_Cys68delinsArg and p.Ser96Ter KITLG could be detected. These data suggest that mutations in KITLG associated with NS-UHL/AHL have a loss-of-function effect. We speculate that the mechanism of the mutation underlying WS2 and leading to membrane incorporation and reduced secretion of KITLG occurs via a dominant-negative or gain-of-function effect. Our study unveils different phenotypes associated with KITLG, previously associated with pigmentation abnormalities, and will thereby improve the genetic counseling given to individuals with KITLG variants.
AuthorsCelia Zazo Seco, Luciana Serrão de Castro, Josephine W van Nierop, Matías Morín, Shalini Jhangiani, Eva J J Verver, Margit Schraders, Nadine Maiwald, Mieke Wesdorp, Hanka Venselaar, Liesbeth Spruijt, Jaap Oostrik, Jeroen Schoots, Baylor-Hopkins Center for Mendelian Genomics, Jeroen van Reeuwijk, Stefan H Lelieveld, Patrick L M Huygen, María Insenser, Ronald J C Admiraal, Ronald J E Pennings, Lies H Hoefsloot, Alejandro Arias-Vásquez, Joep de Ligt, Helger G Yntema, Joop H Jansen, Donna M Muzny, Gerwin Huls, Michelle M van Rossum, James R Lupski, Miguel Angel Moreno-Pelayo, Henricus P M Kunst, Hannie Kremer
JournalAmerican journal of human genetics (Am J Hum Genet) Vol. 97 Issue 5 Pg. 647-60 (Nov 05 2015) ISSN: 1537-6605 [Electronic] United States
PMID26522471 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2015 The American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.
Chemical References
  • RNA, Messenger
  • Stem Cell Factor
Topics
  • Alleles
  • Animals
  • Female
  • Fluorescent Antibody Technique
  • Genetic Linkage
  • Hearing Loss, Unilateral (genetics, metabolism, pathology)
  • Humans
  • Male
  • Mice
  • Mutation (genetics)
  • NIH 3T3 Cells
  • Pedigree
  • Phenotype
  • Prognosis
  • RNA, Messenger (genetics)
  • Real-Time Polymerase Chain Reaction
  • Reverse Transcriptase Polymerase Chain Reaction
  • Stem Cell Factor (genetics)
  • Waardenburg Syndrome (genetics, metabolism, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: